Show simple item record

dc.contributor.authorFazio, N
dc.contributor.authorCarnaghi, C
dc.contributor.authorBuzzoni, R
dc.contributor.authorValle, Juan W
dc.contributor.authorHerbst, F
dc.contributor.authorRidolfi, A
dc.contributor.authorStrosberg, J
dc.contributor.authorKulke, M
dc.contributor.authorPavel, M
dc.contributor.authorYao, J
dc.date.accessioned2018-05-14T20:57:24Z
dc.date.available2018-05-14T20:57:24Z
dc.date.issued2018
dc.identifier.citationRelationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors (NETs): a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. 2018, 211: Neuroendocrinologyen
dc.identifier.urihttp://hdl.handle.net/10541/621011
dc.titleRelationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors (NETs): a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.
dc.typeMeetings and Proceedingsen
dc.contributor.departmentEuropean Institute of Oncology, Milan, Italyen
dc.identifier.journalNeuroendocrinologyen


This item appears in the following Collection(s)

Show simple item record